LA MONICA Silvia | Teaching staff

U-GOV IRIS - Ultime pubblicazioni:

155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models

Year: 2018

Author/s: Morgillo, F.; Corte, C. M. Della; Alfieri, R.; Petronini, P.; La Monica, S.; Papaccio, F.; Ciardiello, F.
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report

Year: 2018

Author/s: Rihawi, K; Alfieri, R; Fiorentino, M; Fontana, F; Capizzi, E; Cavazzoni, A; Terracciano, M; La Monica, S; Ferrarini, A; Buson, G; Petronini, Pg; Ardizzoni, A
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models

Year: 2018

Author/s: Della Corte, Carminia Maria; Ciaramella, Vincenza; Cardone, Claudia; La Monica, Silvia; Alfieri, Roberta; Petronini, Pier Giorgio; Malapelle, Umberto; Vigliar, Elena; Pepe, Francesco; Troncone, Giancarlo; Castellone, Maria Domenica; Troiani, Teresa; Martinelli, Erika; Ciardiello, Fortunato; Morgillo, Floriana
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC

Year: 2018

Author/s: Minari, Roberta; Bordi, Paola; La Monica, Silvia; Squadrilli, Anna; Leonetti, Alessandro; Bottarelli, Lorena; Azzoni, Cinzia; Lagrasta, Costanza Anna Maria; Gnetti, Letizia; Campanini, Nicoletta; Petronini, Pier Giorgio; Alfieri, Roberta; Tiseo, Marcello
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

Year: 2018

Author/s: Cretella, Daniele; Ravelli, Andrea; Fumarola, Claudia; LA MONICA, Silvia; Digiacomo, Graziana; Cavazzoni, Andrea; Alfieri, Roberta; Biondi, Alessandra; Generali, Daniele; Bonelli, Mara; Petronini, Pier Giorgio

Publications:

Functional and morphological characterisation of human colonoid-derived monolayers under inflammatory conditions

Year: 2025

Author/s: Parente I. A., Chiara L., Flammini L., Viglioli M., Vacondio F., Gaiani F., De'Angelis G. L., Pagano Mariano M., La Monica S., Barocelli E., Bertoni S.
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666)

Year: 2025

Author/s: Cavazzoni A., Digiacomo G., Alfieri R., La Monica S., Fumarola C., Galetti M., Bonelli M., Cretella D., Barili V., Zecca A., Giovannetti E., Fiorentino M., Tiseo M., Petronini P. G., Ardizzoni A.
Correction to: The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells (Journal of Experimental & Clinical Cancer Research, (2018), 37, 1, (72), 10.1186/s13046-018-0741-3)

Year: 2025

Author/s: Cretella D., Ravelli A., Fumarola C., La Monica S., Digiacomo G., Cavazzoni A., Alfieri R., Biondi A., Generali D., Bonelli M., Petronini P. G.
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments

Year: 2024

Author/s: Fumarola Claudia, La Monica Silvia, Bonelli Mara, Zoppi Silvia, Alfieri Roberta, Galetti Maricla, Gnetti Letizia, Campanini Nicoletta, Pozzi Giulia, Cavazzoni Andrea, Mazzaschi Giulia, Silini Enrico Maria, Buti Sebastiano, Petronini Pier Giorgio
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models

Year: 2024

Author/s: La Monica Silvia, Vacondio Federica, Eltayeb Kamal, Lodola Alessio, Volta Francesco, Viglioli Martina, Ferlenghi Francesca, Galvani Francesca, Galetti Maricla, Bonelli Mara, Fumarola Claudia, Cavazzoni Andrea, Flammini Lisa, Verzè Michela, Minari Roberta, Petronini Pier Giorgio, Tiseo Marcello, Mor Marco, Alfieri Roberta